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RNA dependent RNA polymerases (RdRp) are essential enzymes for ﬂavivirus replication. Starting from
an in silico docking analysis we identiﬁed a pyridobenzothiazole compound, HeE1-2Tyr, able to inhibit
West Nile and Dengue RdRps activity in vitro, which proved effective against different ﬂaviviruses in cell
culture. Crystallographic data show that HeE1-2Tyr binds between the ﬁngers domain and the priming
loop of Dengue virus RdRp (Site 1). Conversely, enzyme kinetics, binding studies and mutational analyses
suggest that, during the catalytic cycle and assembly of the RdRp-RNA complex, HeE1-2Tyr might be
hosted in a distinct binding site (Site 2). RdRp mutational studies, driven by in silico docking analysis,
allowed us to locate the inhibition Site 2 in the thumb domain. Taken together, our results provide
innovative concepts for optimization of a new class of anti-ﬂavivirus compounds.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The genus Flavivirus belongs to the Flaviviridae family and
consists of over seventy related members, mostly transmitted by
arthropods, and pathogenic to humans (Mackenzie et al., 2004).
Among them, Dengue virus (DENV), West Nile virus (WNV), Japa-
nese Encephalitis virus (JEV), Yellow fever virus (YFV), and lately
Zika virus, are considered important pathogens that occupy aymerase; HeE1-2Tyr, N-{[8-
]benzothiazol-4-yl]
est Nile virus; JEV, Japanese
atitis C virus.
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B.V. This is an open access article uspecial area within the RNA virus world (Daep et al., 2014). Flavi-
viral infections are classiﬁed by the World Health Organization
(WHO) as neglected tropical diseases (NTDs); nevertheless, a well-
established body of environmental, demographic, and ecological
evidences suggest that known and/or novel ﬂavivirus are likely to
spread to other regions of the word in the near future (http://www.
who.int/csr/don/21-october-2015-zika/en/).
Flaviviruses are small, enveloped, RNA viruses whose genome
consists of a 11 kb 5'-capped (þ)ss-RNA that encodes for a single
polyprotein, which is processed to yield three structural and seven
non-structural (NS) proteins. The expression of NS proteins induces
modiﬁcations on the host endoplasmic reticulum where viral
replication takes place (Welsch et al., 2009). NS5 is a multi-domain
protein endowed with N-terminal methyltransferase activity and
C-terminal RNA-dependent RNA polymerase (RdRp) activity. RdRp
replicates (þ)RNA into (-)RNA that is later used as a template to
produce large excess of the viral genome. It has been shown that
NS5 initiates RNA synthesis de novo (i.e. primer-independent) using
a conserved loop (the priming loop) that protrudes from the RdRpnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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initiation complex (Selisko et al., 2012).
An effective and speciﬁc therapy against ﬂaviviruses is currently
not available; even the broad-spectrum antiviral compound riba-
virin appears ineffective for treating ﬂavivirus infections (Leyssen
et al., 2000; Malinoski et al., 1990). In the search for new antivi-
rals, a promising strategy is to target the viral polymerase, as shown
by the results obtained versus HIV reverse transcriptase, and with
the HCV NS5B inhibitors, currently in clinical use. Although a
number of DENV (and to less extent of WNV) NS5 RdRp inhibitors
have been reported, to date none of these passed efﬁcacy/safety
tests in animals or in clinical trials (Lim et al., 2015; Xu et al., 2015).
In the context of a drug discovery program targeting ﬂavivirus
RdRp, we ﬁrstly analyzed in silico a focused library consisting of 203
published (Manfroni et al., 2014a,b; Barreca et al., 2013; Manfroni
et al., 2012) and unpublished compounds, designed to target spe-
ciﬁcally HCV NS5B RdRp. The results of such in silico screening vs.
DENV RdRp brought us to the biochemical and crystallographic
characterization of one selected compound, HeE1-2Ty, that proved
to be a micromolar inhibitor of ﬂavivirus RdRp. Importantly, this
pyridobenzothiazole-based compound, showed speciﬁc antiviral
activity (in the micromolar range) in cell cultures against a panel of
different ﬂaviviruses. Here we report the chemical synthesis of
HeE1-2Tyr, together with the crystal structure of the DENV (sero-
type 3, DENV3) RdRp/HeE1-2Tyr complex, and describe its
biochemical characterization as a DENV3 RdRp inhibitor. To exert
its RdRp inhibitory activity, HeE1-2Tyr exploits an inhibition and
binding mechanism, new to RdRp, which might be extended to the
design of a new class of inhibitory compounds.2. Materials and methods
2.1. Preparation of N-{[8-(Cyclohexyloxy)-1-oxo-2-phenyl-1H-
pyrido[2,1-b][1,3]benzothiazol-4-yl]carbonyl}-L-tyrosinate (HeE1-
2Tyr)
For general methods: see Supplementary material.
A solution of methyl ester 6 (150 mg, 0.3 mmol) and aq 1N LiOH
(0.9 mmol) in 1,4-dioxane (5 mL) was stirred for 0.5 h at room
temperature. The mixture was poured into ice/water, acidiﬁed with
2N HCl (pH ¼ 3) and extracted three times with EtOAc. The com-
bined organic layers were washed two times with brine, dried, and
evaporate under vacuum to give a crude solid which was puriﬁed
by ﬂash column chromatography eluting with CHCl3/MeOH (90:10)
affording the title compound HeE1-2Tyr (87 mg, 50%) as yellow
solid: mp 260e262 C; TLC (CHCl3/MeOH, 80:20 v/v): Rf ¼ 0.40;
[a]D ¼ 0.36 (0.5% p/v, MeOH); 1H NMR (400 MHz, DMSO-d6):
d 12.80 (brs, 1H, Tyr-CO2H), 9.20 (brs, 1H, Tyr-OH), 8.90e8.80 (m,
2H, Tyr-NH and H-9), 8.50 (s, 1H, H-3), 7.90 (d, J ¼ 8.7 Hz, 1H, H-6),
7.80e7.75 (m, 2H, Ar-H), 7.50e7.45 (m, 2H, Ar-H), 7.40e7.35 (m, 1H,
Ar-H), 7.20 (dd, J¼ 2.2 and 8.7 Hz,1H, H-7), 7.15e7.10 (m, 2H, Tyr Ar-
H), 6.65e6.60 (m, 2H, Tyr Ar-H), 4.70e4.60 (m, 1H, Tyr-CH),
4.45e4.35 (m, 1H, Cy-CH), 3.10 (dd, J ¼ 4.7 and 13.9 Hz, 1H, Tyr-
CHAHB), 2.90 (dd, J ¼ 10.5 and 13.9 Hz, 1H, Tyr-CHAHB), 2.00e1.85
and 1.75e1.60 (each m, 2H, Cy-CH2), 1.55e1.20 (m, 6H, Cy-CH2); 13C
NMR (100 MHz, DMSO-d6): d 173.81, 164.49, 161.32, 156.31, 156.29,
151.89, 138.98, 136.77, 133.92, 130.41, 129.36, 128.47, 127.83, 127.89,
123.13, 122.39, 120.90, 116.50, 115.45, 107.52, 105.37, 75.66, 55.13,
36.09, 31.57, 25.52, 23.48; HRMS (m/z): [M]þ calcd. for
C33H30N2O6S, 583.1902; found 583.1908; LC-MS: ret. time 7.35 min.
Chiral HPLC: ret timeZwix-(þ) 5.16 min; ret timeZwix-() 12.12min, ee:
100%.2.2. In silico docking
The AutoDock 4.2 software package (Morris et al., 2009) was
used for a docking search on a library with 203 compounds
developed as potential HCV RdRp inhibitors (Manfroni et al.,
2014a,b; Barreca et al., 2013; Manfroni et al., 2012). Brieﬂy, the
atomic coordinates of the DENV3 RdRp (pdb-id: 2J7U; (Yap et al.,
2007)) were chosen as a rigid protein model, removing all water
molecules. The protein was prepared using the program Python
Molecule Viewer 1.4.5 (http://mgltools.scripps.edu/packages/pmv),
adding hydrogen atoms and Kollman charges.
2.2.1. In silico docking around the protein active site
The RdRp protein model was employed to build a discrete grid
within a box of 22.1  29.6  22.1 Å3, centered near the side chain
of Trp795 (Autogrid 4.2; grid step size: 0.375 Å) as the explored
volume for the docking search. All the compound formulas from the
focused library (2D sdf format) were processed with MolConvert
(ChemAxon Ltd) to generate 3D sdf format; the program Open
Babel (O'Boyle et al., 2011) then converted all sdf into pdb ﬁles.
After the addition of Gasteiger charges, and of the rotational con-
straints on everymolecule in the library (MGLTools package: http://
mgtools.scripps.edu/), a 'docking parameter ﬁle' was generated for
each compound, to perform 30 independent genetic algorithm runs
in the docking procedure. The results were analyzed with Python
Molecule Viewer 1.4.5. The best two molecules (DG values 10.05
and 9.52 kcal/mol), were selected to be tested in in vitro activity
assays.
2.2.2. In silico docking around the thumb domain
For the purpose of a second docking analysis (see below), the
priming loop of the protein (from His786 to Asp808) was removed
from the pdb, leaving an open gap in the polypeptide chain. The
protein was then prepared using the program Python Molecule
Viewer 1.4.5 as described before. The protein model was employed
to build a discrete grid within a box of 22.9  22.9  22.9 Å3 di-
mensions, centered near the thumb domain residue Ala757. A
search for the best docking sites ofHeE1-2Tyrwas performed using
AutoDock 4.2 (60 genetic algorithm runs).
2.3. Cloning, expression and puriﬁcation of the DENV3 RdRp
domain
DENV3 RdRp (amino acids 272-900) was cloned into pET15b
with a His6-tag at the N-ter, and expressed in E. coli BL21pLys cells
(Noble et al., 2013). Cells were grown at 37 C to an OD600 0.8,
induced with 0.4 mM isopropyl b-D-thiogalactopyranoside (IPTG)
and further incubated O/N at 15 C. Cells were harvested by
centrifugation and the pellet was resuspended in 20 mM Na HEPES
at pH 7.0, 300 mMNaCl, 5 mM imidazole, DNase I (2 mg/ml), 20 mM
MgSO4 and EDTA-free complete protease inhibitors (Roche), and
lysed using a cell disruptor (Basic Z Bench top 0.75 KW; Constant
System). The lysate was clariﬁed by centrifugation at 18,000 rpm
for 1 h at 4 C. The supernatant was puriﬁed through a 5 ml bed
volume HiTrap nickel immobilized metal ion afﬁnity chromatog-
raphy column (G.E. Healthcare) connected to a FPLC system (G.E.
Healthcare), after washing unbound protein with buffer A (20 mM
Na HEPES at pH 7.0, 300 mM NaCl, EDTA-free complete protease
inhibitors (Roche)) with 60 mM imidazole; RdRp was then eluted
with buffer Aþ 255mM imidazole. To remove the N-terminal His6-
tag, 500 U of thrombin (Sigma) was added to the pooled fraction
containing the RdRp, and the mixture was dialyzed O/N at 4 C
against 1 l of buffer A supplemented with 5 mM TCEP. DENV3 RdRp
was further puriﬁed by size exclusion chromatography (Superdex
200) using the same buffer. The purity of the resulting RdRp was
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8 mg/ml using a 10-kDa molecular mass cut-off centrifugal
concentrator (Millipore), divided into aliquots and stored at20 C.
For expression and puriﬁcation of WNV RdRp see Supplementary
material.
2.4. DENV3 and WNV RdRp inhibition assay
RdRp activity was assessed in vitro following the synthesis of
double-stranded RNA from a single-stranded RNA poly(C) template
(Sigma-Aldrich P4903) (1 mg ﬁnal quantity) and 100 mM GTP, in a
reaction mixture containing 20 mM Tris/HCl (pH 7.5), 1 mM DTT,
25 mM NaCl, 5 mM MgCl2, 0.3 mM MnCl2, 2 U RiboLock Ribonu-
clease inhibitor (Life technologies), 1 ml PicoGreen Quantitation
Reagent (Life technologies). Before starting the reaction, 1 mM ﬁnal
concentration of the protein was added to the mixture together
with the inhibitor (from 0 to 50 mM). The reactions were followed
for 1 h at 30 C on a TECAN Inﬁnite 200 PRO microplate reader,
measuring the growth of PicoGreen ﬂuorescence (Ex/Em ¼ 485/
530 nm) due to the formation of dsRNA. The ﬁnal ﬂuorescence
values were calculated as the average of four independent experi-
ments. Measurements of activity (i.e. linear slope of ﬂuorescence
increase in time) vs. inhibitor concentration were used to estimate
the IC50 values of the two in silico selected compounds using the
program GraFit5 (Erithacus software), and the equation Y¼(Range/
(1þ(X/IC50)S), where Range is the value observed for the uninhib-
ited RdRp, and s is a slope factor.
2.5. DENV3 and WNV RdRp/HeE1-2Tyr inhibition kinetic assay
Enzyme kinetics experiments were performed in order to gain
insight on the inhibitionmechanism ofHeE1-2Tyr relative to either
the poly(C) RNA template or the GTP substrate. Brieﬂy, we per-
formed standard enzymatic reactions on both DENV3 and WNV
RdRps in the presence of increasing amounts of the inhibitor (from
0 to 4 mM) where: i. the poly(C) concentration was varied (from
78 ng to 10 mg, in 200 ml ﬁnal volume) at constant GTP concentra-
tion (100 mM); or ii. the GTP concentration was varied (from 0 to
1 mM), at 10 mg poly(C) constant concentration in 200 ml reaction
volume. The assayswere performed using a TECAN Inﬁnite 200 PRO
microplate reader; the results were analyzed through Line-
weavereBurk plots (1/V versus 1/[S]) at varying HeE1-2Tyr
concentrations.
2.6. In cell inhibition assays
2.6.1. Strain information
DENV-1 Djibouti (strain D1/H/IMTSSA/98/606),
PMID:11369871; DENV-2 Martinique (strain H/IMTSSA-MART/98-
703), PMID:11027645; DENV-3 Bolivia (strain 4025),
PMID:19505253; DENV-4 Dakar (strain HD34460, WRCEVA); WNV
Uganda 956 D117, WRCEVA; YFV Bolivia 88-99; YFV Sudan M 90-5
TVP 3230, WRCEVA, YFV Uganda MR896 TVP 3236, WRCEVA; YFV
Nigeria A-Adeoye TVP 3223, WRCEVA. Sequence of primers and
probe are available on request.
2.6.2. Antiviral assay
The amount of each virus in the assay was calibrated such that
the replication growth was not yet plateaued at readout time,
depending on the virus species (day 4 for most DENVs, and day 3
for WNV and YFV). Approximate MOI (Multiplicity Of Infection)
varies from 0.2 to 0.01 depending on the virus strain. One day prior
to infection, 5  104 Vero E6 cells (or 105 HEK 293 cells for YFV
assay) were seeded in 100 ml of medium (with 2.5% FCS) in each
well of 96-well cell culture plates. The next day, 8 serial two-folddilutions of the compound (from 20 mM to 0.16 mM), in duplicates
or triplicates, were added to the cells (25 ml/well, in 2.5% FCS con-
taining medium). Four Virus Control (VC) wells (per virus) were
supplemented with 25 ml of medium. Fifteen minutes later, 25 ml
per well of medium (2.5% FCS), containing the appropriate amount
of diluted viral stock, were added to the 96-well plates.
Cells were cultivated for 3 or 4 days, after which 100 ml of the
supernatant were collected for viral RNA puriﬁcation. The infected
supernatants were transferred to 96 wells S-Bloc from QIAgen,
preloaded with VXL lysis buffer mix and extracted by the Cador
Pathogen 96 QIAcube HT kit ran on QIAcube HT automat according
to the manufacturer protocol. Puriﬁed RNAs were eluted in 80 ml.
Viral RNAs were then quantiﬁed by real time RT-PCR (ABI 7900 HT
Fast Real-Time PCR System) to determine viral RNA yield (Super-
Script III Platinium one-step RT-PCR with Rox from Invitrogen or
GoTaq Probe 1-step RT-PCR system from Promega), using 7.5 ml of
RNA and 12.5 ml of RT-PCR mix using standard cycling parameters.
Four 2-log dilutions of an appropriate T7-generated RNA containing
known quantities of RNA (100 copies to 100 millions copies) were
used to calibrate the quantiﬁcation of each strain and serotype.
Mean inhibition of virus yield in the triplicates or duplicates were
plotted using Kaleidagraph software (Synergy Software) and the
best sigmoidal curve was determined by a macro in this software:
(Inhibition, Y is given by Y ¼ 100/(m0/m1)m2). This macro allowed
us to determine the IC50, half maximal inhibitory concentration.
2.6.3. Cytotoxicity assay
One day prior to the assay 5  104 Vero E6 cells (or 105 HEK
293 cells) were seeded in 100 ml of medium (with 2.5% FCS) in each
well of a 96-well titer plates. The next day, two-fold serial dilutions
of the compounds (from 200 mM to 6.2 mM), in duplicates or trip-
licates, were added to the cells (25 ml/well, in 2.5% FCS). Six cell
control (CC) wells were supplemented with 25 ml medium con-
taining two-fold serial dilution of an equivalent amount of DMSO.
Eight wells were not seeded with cells and served as background
control of ﬂuorescence for the plates. Cells were cultivated for 3
(HEK 293) or 4 (Vero E6) days, after which the supernatant was
removed and replaced with 70 ml of medium containing CellTiter-
Blue reagent (Promega) and further incubated for 90 min at
37 C. Fluorescence of the plates was then read on a TECAN Inﬁnite
M 200 Pro reader. The cell viabilities in percent were calculated as
100 x (mean value of X- Background without cells)/(CC e
background).
2.7. Crystal structure of the DENV3 RdRp in complex with HeE1-
2Tyr
Sitting drop crystallization experiments on DENV3 RdRp (9 mg/
ml) were assembled by means of an Oryx-8 crystallization robot
(Douglas Instruments, East Garston, UK), using 0.3 ml droplets
containing 50/50% of the protein/precipitant solutions, following
the protocol already described (Noble et al., 2013). Crystals were
obtained after 1 week at 20 C, in 20e50mMMgCl2,100mMHEPES
pH 7.5, and 22% w/v Poly(acrylic acid sodium salt). Before X-ray
data collection, crystals were soaked for 48 h in a cryoprotectant
solution (25e55 mM MgCl2, 100 mM HEPES pH 7.5, 22% w/v Pol-
y(acrylic acid sodium salt), and 25% glycerol) containing 10 mM
HeE1-2Tyr in the presence of 10 mg of Poly-C and 100 mM GTP, and
then ﬂash-cooled in liquid nitrogen. The DENV3 RdRp/HeE1-2Tyr
crystals diffracted to a maximum resolution of 3.0 Å using syn-
chrotron radiation on beam-line BM30 at the European Synchro-
tron Radiation Facility (ESRF-Grenoble, France). X-ray diffraction
data were indexed and scaled using XDS (Kabsch, 2010) (Table 1).
The three-dimensional structure of DENV-RdRp/HeE1-2Tyrwas
solved by the Molecular Replacement method using the program
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the DENV3 RdRp 3D structure (PDB-id 4HHJ; (Noble et al., 2013)).
The single RdRp molecule present in the crystal asymmetric unit
was subjected to rigid-body reﬁnement, and subsequently con-
strained reﬁned using REFMAC5 (Steiner et al., 2003). A random set
comprising 5% of the data was omitted from reﬁnement for R-free
calculation. After a few reﬁnement cycles of the free RdRp struc-
ture, additional electron density was clearly visible in the Fo-Fc
map (Fig. 3, left inserts), allowing to ﬁt the HeE1-2Tyr molecule
in a location between the priming loop and the ﬁngers domain.
Manual rebuilding with COOT (Emsley et al., 2010), and additional
reﬁnement with BUSTER (Smart et al., 2012) and REFMAC5 were
subsequently performed. Data collection, reﬁnement statistics as
well as stereochemical quality of the model are summarized in
Table 1. Atomic coordinates and structure factors for DENV3 RdRp
in complex with HeE1-2Tyr have been deposited in the PDB
(Berman et al., 2000), with accession code 5IQ6.
2.8. DENV3 RdRp mutants production
DENV3 RdRp mutants were generated from the pET15b-DENV3
clone using a QuikChange site-directed mutagenesis kit (Stra-
tagene). According to the manufacturer's instructions primers used
for mutagenesis are reported in Supplementary material. DENV3
RdRp mutants were expressed in E. coli BL21pLys cells and puriﬁed
as reported for the wt protein.
2.9. DENV3 RdRp wt and mutants/HeE1-2Tyr binding assays
In vitro inhibitor binding assays were performed at 30 C in a
Varian Cary Eclipse Fluorescence Spectrophotometer, recording Trp
ﬂuorescence spectra between 300 and 400 nm (excitation 280 nm).
10 ml of HeE1-2Tyr (diluted in DMSO from 0 to 50 mM) were addedTable 1
X-ray data-collection and reﬁnement statistics.
Data collection
Beam line & wavelength (Å) ESRF BM30; 0.9798
Space group C2221
Unit-cell parameters (Å) a ¼ 162.0; b ¼ 180.9; c ¼ 58.1
Molecules in a.u. 1
Resolution (Å) 45.5e3.0
Mosaicity () 0.2
Unique reﬂections 17,202 (1279)a
Completeness (%) 97.8 (99.4)
Redundancy 4.0 (4.1)
Rmeasb (%) 18.1 (96.5)
CC(1/2) (%) 98.9 (59.5)
Average I/s (I) 9.7 (1.8)
Final model
R factorc/Rfreed (%) 19.2/26.0
r.m.s. bonds (Å) 0.004
r.m.s. angles () 0.84
Average protein B fac. 65.5
Average ligand B fac. (Å2) 118.8e
Residues in most favored regions (%) 97%
Residues in additionally allowed regions (%) 3%
LLDFf 1.48
ligand RSRg (%) 26.0
PDB-ID 5IQ6
Values in parentheses are for the highest resolution shell.
a (3.08e3.0).
b Rmeas ¼ (S (n/(n-1) S jI - (I)j)/S I x 100, where I is intensity of a reﬂection and (I)
is its average intensity.
c Rfactor ¼ S jFo - Fcj/S jFoj x 100.
d Rfree is calculated on 5% randomly selected reﬂections, for cross-validation.
e Ligand occupancy 1.
f Local Ligand Density Fit.
g Real Space R-value.to 170 ml of protein solution (ﬁnal protein concentration 0.2 mM).
The assay was performed for the wt protein also in the presence of
ssRNA (ﬁnal concentration 0.5 mM). Before the assay we veriﬁed
that HeE1-2Tyr did not absorb/emit in the spectral range selected
for our binding experiments. The values of ﬂuorescence vs. inhibi-
tor concentration were ﬁtted with GraFit 5 (http://www.erithacus.
com/graﬁt/) using the three parameter (M, m, Kd) equation:
F ¼ M  ðM mÞ½PT 
½PIwith ½PI
¼ ½PT  þ ½IT  þ Kd 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½PT  þ ½IT  þ KdÞ2  4½PT ½IT 2
q
2
:
Where F is the ﬂuorescence intensity, [PT]/[IT] are the total protein/
inhibitor concentrations, M/m is the max/min of ﬂuorescence, and
[PI] is the concentration of the protein bound to the inhibitor.3. Results
3.1. Synthesis of HeE1-2Tyr
HeE1-2Tyr was obtained (Fig. 1) revisiting a synthetic route
recently published for the preparation of functionalized pyr-
idobenzothiazoles (Manfroni et al., 2012). According to this pro-
cedure, 2-methylbenzothiazole derivative 1 underwent two
consecutive steps of demolition and reconstruction to produce the
corresponding ethyl 1,3-benzothiazolacetate 2 in low yield and
with poor reproducibility. In order to by-pass the limiting steps of
the original method (Manfroni et al., 2012), compound 1 was
directly functionalized at the C-2 methyl group by reaction with
diethyl carbonate using NaH as a base to yield the acetate derivative
2 in 70% yield. Compound 2 was then reacted with Vilsmeier re-
agent to afford the acrylate derivate 3 which was used to build the
pyridobenzothiazole nucleus of compound 4, employing phenyl
acetic anhydride (Morrill et al., 2014) in neat condition. Ester 4was
hydrolyzed under basic conditions to the corresponding acid 5,
which was coupled with Tyr methyl ester hydrochloride, using
TBTU reagent, to give amide 6 that was then hydrolyzed into target
compound HeE1-2Tyr under mild conditions with LiOH. To eval-
uate the enantiomeric purity of HeE1-2Tyr, its D enantiomer 8was
also synthesized (see Supplementary material for the compound
preparation). Chiral HPLC analysis using the HeE1-2Tyr alone and
in mixture with its D enantiomer 8 highlighted 100% of enantio-
meric excess for both compounds meaning that no racemization
occurred during mild hydrolysis conditions (Fig. S1).3.2. In silico docking search
A virtual screening procedure was applied to select new po-
tential inhibitors of DENV3 RdRp.We performed an in silico docking
search exploring a wide region around the DENV3 RdRp active site
(pdb-id: 2J7U (Yap et al., 2007)), using a proprietary library of
compounds originally focused on HCV RdRp inhibition (Manfroni
et al., 2014a,b; Barreca et al., 2013; Manfroni et al., 2012). The
docking search produced a list of compounds with predicted
binding free energy values ranging between 5.65 kcal/mol
and 10.05 kcal/mol. The top 2 compounds i.e. HeE1-2SO2 (com-
pound 3c in (Manfroni et al., 2012)) and HeE1-2Tyr, characterized
by the lowest docking energy (10.05 kcal/mol and9.52 kcal/mol
respectively; Fig. S3) were selected for in vitro analysis of RdRp
inhibitory activity.
Fig. 1. Synthetic pathway employed for the preparation of HeE1-2Tyr. Reagents and conditions: i) diethyl carbonate, 60% NaH, dry THF, reﬂux; ii) Vilsmeier reagent, 90 C; iii)
phenylacetic anhydride, 110 C, neat; iv) aq. 10% NaOH/MeOH (1:5), 75 C. v) Tyr methyl ester HCl, TBTU, DIPEA, DMSO, rt; vi) aq 1N LiOH, 1,4-dioxane, rt.
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Both HeE1-2Tyr and HeE1-2SO2 (Manfroni et al., 2012) showed
inhibitory activity against DENV3 andWNV RdRps in the mM range.
Since our in vitro inhibition assay is based on ssRNA template (Poly-
C) we could not discriminate between initiation and elongation
phases of RNA polymerization. In particular, HeE1-2SO2 inhibited
DENV3 and WNV RdRps with IC50 ¼ 2.8 ± 0.5 mM and 2.5 ± 1.3 mM,
respectively, whereas HeE1-2Tyr IC50 values against DENV3 and
WNV RdRps were 1.5 ± 0.2 mM and 3.4 ± 0.4 mM, respectively
(Fig. 2A).
Since only HeE1-2Tyr showed inhibition activity in cell-based
assays (see below) we further characterized this compound
analyzing the RdRp kinetic properties in the presence of the in-
hibitor. The LineweavereBurk plots for both DENV3 (Fig. 2 B,C) and
WNV RdRp (not shown) highlighted a non-competitive inhibition
mechanism relative to both the poly(C) and the GTP substrates.3.4. In cell inhibition assays
HeE1-2Tyr and HeE1-2SO2, were tested for antiviral activity in
cell assays (HEK 293 and Vero E6 cells). HeE1-2SO2 did not show
any activity whereas HeE1-2Tyr was able to inhibit an Ugandan
strain of WNV with an IC50 ¼ 2.1 ± 0.7 mM, as well as all the four
DENV serotypes, with IC50 ranging from 6.8 to 15 mM (Table 2). The
cytotoxicity of HeE1-2Tyr versus Vero E6 cells was ~115 ± 35 mM,
allowing a reasonably good selectivity index for a starting hit
compound. Additionally, upon infection of human HEK 293 cells
(CC50 ¼ 50 mM), HeE1-2Tyr was found to inhibit clinical strains of
YFV with IC50 values ranging from 3.9 to 12 mM (Table 2).3.5. DENV3 RdRp/HeE1-2Tyr crystal structure
The crystal structure of DENV3 RdRp/HeE1-2Tyr complex was
obtained after soaking the protein crystals with the inhibitor
(10 mM) in the presence of 10 mg of Poly-C and 100 mM of GTP, for
48 h. Poly-C and GTP were added to promote diffusion and binding
of the inhibitor as observed in our previous works on NorovirusRdRp (Tarantino et al., 2014; Croci et al., 2014a; Croci et al., 2014b).
After the molecular replacement solution and a few reﬁnement
cycles, additional electron density in the Fo-Fc map (Fig. 3, left in-
serts) allowed to ﬁt the HeE1-2Tyr molecule between the priming
loop and the ﬁngers domain (binding Site 1; Fig. 3), at about 10 Å
from the in silico docking site (Fig. S3). Several other crystals,
soaked with 10 mM HeE1-2Tyr in the absence of Poly-C and GTP,
exhibited a similar Fo-Fc map peak in the same zone, thus
excluding a mistaken interpretation of the electron density (e.g.
inhibitor for nucleotides). Interestingly, HeE1-2Tyr, which is a
bulky molecule with a high degree of conformational freedom, is
folded on itself in a rather compact conformation with its phenolic
ring in stacking interaction with the pyridobenzothiazole moiety.
Such closed shape is reminiscent of the stacking interaction of two
RNA bases, and is stabilized by additional stacking with the side
chain of Trp795 in the priming loop (Fig. 3). The structural paral-
lelism between the shape of HeE1-2Tyr and a small RNA fragment
is further reinforced by the presence of the negatively charged
carboxylate group of the inhibitor that mimics the nucleotide
backbone phosphate. HeE1-2Tyr induces only a slight perturbation
of the protein structure (Ca r.m.s.d. of 0.43 Å relative to pdb 4HHJ).
In particular we observed ﬂipping of Val603 jmain chain dihedral
angle by 180, due to steric hindrance of the inhibitor cyclohexane
moiety; this caused the loss of a H-bond with the Asn492 side
chain, that moves away through ~100 side chain rotation. The
inhibitor cyclohexane ring is hosted in a shallow depression of the
protein surface in close contact with the amino acids 603-606 and
with the side chain of Asn492.
The HeE1-2Tyr binding site (Site 1) matches the site already
observed for the DENV RdRp inhibitor NITD107 (pdb-id 3VWS
(Noble et al., 2013)), where, in place of the two stacking rings of
HeE1-2Tyr, two inhibitor molecules (arranged in antiparallel
stacking interaction) are present. Very recently, the crystal struc-
tures of a new class of potent DENV RdRp non-nucleoside inhibitors
have been published (Noble et al., 2016; Yokokawa et al., 2016),
showing that the compounds bind in a cavity formed by the
priming loop and the thumb domain. Such cavity and the HeE1-
2Tyr Site 1 are separated by the tip of the priming loop (amino acids
Fig. 2. HeE1-2Tyr RdRp inhibition. A The inhibitory effect of HeE1-2Tyr on DENV3 and WNV RdRp activity was measured by the decrease in relative ﬂuorescence growth rate (a%
corresponds to the ﬂuorescence growth rate expressed in percentage of the growth rate without the inhibitor). An average result of four independent experiments is shown, with
error bars indicating standard deviations. B Lineweaver-Burk double reciprocal plot showing the HeE1-2Tyr non-competitive inhibition mechanism on DENV3 RdRp, relative to the
PolyC template, with a Ki values of 0.64 ± 0.09 mM. C Lineweaver-Burk double reciprocal plot showing the HeE1-2Tyr non-competitive inhibition mechanism on DENV3 RdRp,
relative to the GTP substrate, with Ki values of 1.96 ± 0.20 mM. B and C are the average results of four independent experiments.
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Overall, HeE1-2Tyr appears to mimic the possible initial inter-
action between template RNA and the enzyme during the ﬁrst steps
of RNA polymerization. Therefore, the crystal structure would
suggest that the inhibitor may interfere with the incoming RNA
template, in principle hinting at a competitive inhibition mecha-
nism vs. the RNA substrate (Fig. 3). To validate such hypothesis we
performed a Trp ﬂuorescent binding assay, in the absence/presence
of ssRNA. The Kd values obtained were not affected by the presence
of the substrate (Kd ¼ 5.5 ± 0.3 mM and 5.8 ± 0.6 mM in the absence/
presence of ssRNA, respectively).3.6. DENV3 RdRp Trp795Ala and Asn492Phe mutants
To further characterize the protein-inhibitor interactions we
produced two point mutants, Asn492Phe and Trp795Ala, to modify
residues of the inhibitor binding site. The binding afﬁnity of HeE1-
2Tyr for the Asn492Phe RdRp mutant was unaffected (DENV3 wt
RdRp Kd ¼ 5.5 ± 0.3 mM vs Asn492Phe Kd ¼ 4.5 ± 0.8 mM, Fig. 4). On
the contrary, HeE1-2Tyr dissociation constant for the Trp795Ala
mutant increased by a factor of 2, to 10.5 ± 0.5 mM (Fig. 4). As a
result, the polymerase activity of both mutants was inhibited by
HeE1-2Tyr to the same extent observed for the wt RdRp (the po-
lymerase activity of the protein was unaltered by the two
mutations).The experimental results described above outline a conceptual
discrepancy between the crystallographic data (suggesting a
competitive inhibition mechanism), the inhibition kinetics
(consistent with a non-competitive inhibition mechanism) and the
two RdRp mutants that, despite the designed perturbation of the
ligand binding site, are inhibited by HeE1-2Tyr to the same extent
of the wt enzyme.3.7. DENV3 RdRp Cys753Glu and Arg749Ala mutants
In order to address the above mentioned discrepancy, we
speculated that during the enzyme catalytic cycle the RdRp priming
loop must move out of the active site to make room for the crescent
dsRNA. The priming loop relocation during RNA elongation might
thus expose a previously buried portion of the thumb domain
where HeE1-2Tyr may bind as a non-competitive inhibitor.
To test such hypothesis we deleted in silico the RdRp priming
loop, i.e. amino acids comprised between His786 and Asp808
(leaving an open gap in the polypeptide chain), exposing a new
region of the thumb subdomain (we refer to such modiﬁed RdRp
model as RdRp*). The newly exposed region was then explored in
silico, searching for alternative HeE1-2Tyr docking site(s). The
docking procedure allowed to identify a new potential binding site
for HeE1-2Tyr (Site 2; Fig. 5; binding DG ¼ 8.69 kcal/mol; pre-
dicted Ki ¼ 0.43 mM) located at the N-terminal end of the 750-776
Fig. 3. Crystal structure of DENV3 RdRp in complex with HeE1-2Tyr. HeE1-2Tyr (sticks with orange carbon atoms) bound to RdRp (gray cartoon): the priming loop is shown as
blue cartoon, Trp795 and Asn492 interacting with the inhibitor, are shown as blue sticks. Template and newly formed RNA have been superimposed on the crystal structure as red
and pink cartoons, respectively, to illustrate possible inhibitor interference with protein activity (modeled from the structure of Norwalk Virus polymerase, pdb-id 3BSO). Left
inserts: the Fo-Fc electron density map contoured at 2.5 sigma calculated after the initial reﬁnement cycles without the inhibitor (shown for reference). Picture drawn with Pymol
(www.pymol.org). Lower right insert: HeE1-2Tyr chemical structure. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
Table 2
Cell-based inhibitions and cytotoxicity of HeE1-2Tyr and reference compound NITD
008.
HeE1-2Tyr NITD 008
CC50
Vero E6 115 ± 35a >100
IC50
DENV-1 Djibouti 6.8 0.39
DENV-2 Martinique 15 ± 5 0.82
DENV-3 Bolivia 10 ± 0.6a 0.8
DENV-4 Dakar 7.7 ± 2.2a ND
WNV Uganda 2,1 ± 0,7a 0.85
CC50
HEK-293 50 ± 10a ND
IC50
YFV Bolivia 3.9 ± 1.4a 0.35 ± 0.1a
YFV Uganda 8.3 ND
YFV Nigeria 12 ND
YFV Sudan 3.1 0.27
Dengue viruses andWNVwere assayed in Vero E6 cells. YFV strains were assayed in
HEK 293 cells. Individual CC50 and IC50 values (in mM) are the mean of triplicates. a
indicates mean and variance of two or three independent experiments.
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extended conformation in Site 2, stabilized by several interactions
with the protein, such as H-bonds to Cys753, to the main chain of
Pro784, and a salt bridge to Arg749 (Fig. 5).
In order to validate the results of such computational model we
produced two point mutations on wt RdRp (Cys753Glu and
Arg749Ala; Fig. 5), predicted to perturb the HeE1-2Tyr binding to
Site 2. Since Site 2 is not accessible when the protein is not involvedin the catalytic cycle, the afﬁnity of the protein forHeE1-2Tyr is not
affected by the two point mutations (Kd ¼ 5.2 ± 0.3 mM and
5.7 ± 0.5 mM for Cys753Glu and Arg749Ala, respectively). In the
presence of the Cys753Glu mutation, RdRp proved slightly less
susceptible to HeE1-2Tyr inhibition (IC50 raised from 1.5 ± 0.2 mM
(wt) to 5.0 ± 0.8 mM (Fig. 6). Moreover, even if the Arg749Ala mu-
tation produced a considerable decrease in protein activity (~80%
drop), suggesting an involvement of Arg749 in RNA binding, the
residual protein activity was unaffected by HeE1-2Tyr up to an
inhibitor concentration of 50 mM (Fig. 6), in keeping with the mu-
tation design aims. Thus, the mutational results suggest that the
Site 2 region is relevant for RdRp inhibition by HeE1-2Tyr.
4. Discussion
HeE1-2Tyr is ﬁrstly presented here as a new inhibitor of DENV3
RdRp endowed with signiﬁcant inhibitory activity against DENV
and other ﬂaviviruses (i.e. WNV, YFV) in cell cultures. Nevertheless,
the biochemical and structural analyses presented entail a series of
conﬂicting results. In particular, we observed an evident discrep-
ancy between the crystal structure, which would suggest that
HeE1-2 Tyr at Site 1 competes with RNA binding, and the non-
competitive inhibition mechanism highlighted by the kinetics
data. Such discrepancy was further stressed by the observation that
a selected point mutation expected to perturb the inhibitor binding
site (Trp795Ala in the priming loop) did not decrease HeE1-2Tyr
inhibitory activity in vitro, suggesting that the inhibition site might
be different from the binding site observed in the crystal structure.
In order to address such incongruity we speculated that, when the
enzyme is bound to the crescent dsRNA, the inhibitor cannot bind
to the priming loop with the same modality observed in the crystal
Fig. 4. Binding of DENV3 RdRp to HeE1-2Tyr. The binding of the HeE1-2Tyr to RdRp wt, Asn492Phe mutant and Trp795Ala mutant was monitored following the variation of
protein Trp ﬂuorescence (with a peak around 340 nm). The insert panel shows the experimental curves collected for the wt protein.
Fig. 5. in silico docking of HeE1-2Tyr on RdRp without the priming loop. HeE1-2Tyr (sticks with orange carbon atoms) docked on the thumb domain of RdRp (green cartoons),
interacting with Arg749, Cys753 and other amino acids (shown as sticks with green carbon atoms) after the deletion of the priming loop. The lower insert shows the overall protein
structure with the omitted priming loop (yellow cartoon) and the extent of the region explored with the new in silico docking search. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
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conformational change during transition from the initiation to the
elongation complex. The priming loop, after its initial role in
assisting replication of the ﬁrst nucleotides, must move out of the
RdRp active site to allow the accommodation of the growing dsRNA(Choi and Rossmann, 2009; Selisko et al., 2012) (modeled in Fig. 3).
Hence, we speculated that relocation of the priming loop during
RNA elongation might expose a previously buried portion of the
thumb domainwhereHeE1-2Tyrmight bind to exert its function as
a non-competitive inhibitor. To verify such hypothesis we
Fig. 6. Inhibition of Cys753Glu and Arg749Ala mutants. The inhibitory activity of HeE1-2Tyr on RdRp of DENV3 wt (black curve), Cys753Glu (red curve) and Arg749Ala (green
curve) mutants was measured by the decrease in relative ﬂuorescent slope (a% is the ﬂuorescence over time slope expressed in percentage of the same slope in the absence of the
inhibitor). An average result of four independent experiments is shown, with errors bars indicating standard deviations. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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of RdRp* (priming loop deleted), to mimic the protein state ach-
ieved during RNA elongation. Such procedure allowed us to pro-
pose Site 2 as a new possible binding site for HeE1-2Tyr. We
demonstrated that the mutation of either Cys753Glu or Arg749Ala
expected to perturb inhibitor binding, caused a drop of HeE1-2Tyr
inhibitory potency.
It is known that hepatitis C virus RdRp activity is affected by
non-nucleoside allosteric inhibitors that bind four different sites
distal to the enzyme active site; two of these are located in the palm
domain, and two in the thumb domain (Barreca et al., 2011;
Haudecoeur et al., 2013). Notably, their mechanism of RdRp inhi-
bition is not conclusively known; however it has been suggested
that certain inhibitors act by preventing conformational changes
that alter both the structure and internal protein dynamics crucial
for RNA replication (Davis and Thorpe, 2013). Interestingly, the
location of DENV3 RdRp Site 2 in the thumb domain is different
from that of the thumb Site I and II in HCV polymerase (Haudecoeur
et al., 2013). Site 2 resides along the exit pathway of the newly
formed dsRNA (Fig. 3), therefore HeE1-2Tyr inhibition can be (at
least partially) due to a hindering action on the polymerase
translation along the RNA. Furthermore, Site 2 is distant from the
NS5 methyltransferase-polymerase interface (Zhao et al., 2015)
(mainly involving the ﬁngers domain of RdRp), which is then un-
likely to be affected by HeE1-2Tyr binding.
Despite the biochemical data collected so far, we cannot rule out
that, besides RdRp, other ﬂaviviral proteins might be affected by
HeE1-2Tyr, also considering the inhibitor's potential structural
similarity with a dinucleotide in stacking conformation. Never-
theless, the preliminary data of HeE1-2Tyr activity in infected cells
are encouraging, and suggest that synergism with further molec-
ular design and biophysical data can lead to a new class of potent
and selective anti ﬂaviviral compounds.Funding information
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